Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Completed 6Unknown 4Withdrawn 2Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4NET 1Endocrine 1

Conditions

Neuroblastoma 3Recurrence 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neoplasms 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Unknown × 3-Iodobenzylguanidine × Clear all
NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown
60 enrolled
CNS

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT02771743 2016-05-24

Response-based Treatment of High-risk Neuroblastoma

Samsung Medical Center

Phase 2 Unknown
54 enrolled
CNS

Neuroblastoma

NCT00013806 2005-06-24

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

National Center for Research Resources (NCRR)

Phase 2 Unknown
CNS

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡